Abstract
Intravesical therapy is the gold standard in the treatment of nonmuscle invasive bladder cancer (NMIBC). Despite the efficacy of intravesical therapies, the best treatment options are not determined yet. Development in research of bladder cancer shows several new intravesical drugs and its delivery systems. Additionally, the novel knowledge of bladder cancer immune reaction improves and provides ambitious treatment strategies. The future of NMIBC therapy will be changed by the development of immunotherapy and new technologies for device-assisted treatment. This review focuses on recent advances in the intravesical therapy of NMIBC, viral gene therapy, new technology of intravesical chemotherapy, and drug delivery system.
Publisher
Korean Urological Oncology Society